S-1: Novo Integrated Sciences Files for Resale of 3.5 Million Shares Following Convertible Note Issuance

Novo Integrated Sciences has filed a registration statement for the resale of up to 3.5 million shares of common stock by a selling securityholder following the conversion of a secured convertible promissory note.

Summary

• Novo Integrated Sciences, Inc. has filed a Form S-1 registration statement with the SEC to register the resale of up to 3,500,000 shares of its common stock.
• These shares are issuable upon the conversion of a secured convertible promissory note with a principal amount of $6,210,000 held by Streeterville Capital, LLC.
• The convertible note was issued on April 5, 2024, with a maturity date of April 8, 2025.
• Novo Integrated Sciences received $5,550,000 for the note, after deducting an original issue discount of $660,000 and $50,000 for the selling securityholder's transaction costs.
• The selling securityholder may convert the note into common stock on any trading day when the intraday trade price is 10% greater than the previous day's closing price.
• The conversion price is 85% of the lowest daily volume-weighted average price of the common stock during the five trading days before the conversion date.
• The company will not receive any proceeds from the resale of these shares by the selling securityholder.
• The company will bear the costs of registering the securities, while the selling securityholder will bear any commissions or discounts from their sale.
• The company's common stock is listed on the Nasdaq Global Market under the symbol NVOS, and the closing price on July 5, 2024, was $0.7599 per share.
• Novo Integrated Sciences is a smaller reporting company and has elected to comply with certain reduced reporting requirements.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The document primarily outlines the terms of a securities offering for resale, without expressing strong positive or negative views about the company's prospects. The presence of risk factors tempers any potential optimism.

Positives

• The company has secured financing through the issuance of a convertible note.
• The registration of resale shares allows the selling securityholder to potentially liquidate their investment.
• The company is not burdened with paying commissions or discounts related to the resale of shares by the selling securityholder.

Negatives

• The company will not receive any proceeds from the resale of the shares.
• The conversion of the note could dilute existing shareholders' equity.
• The selling securityholder may sell shares at varying prices, potentially impacting the market price of the stock.
• The company is required to seek shareholder approval for the issuance of additional shares if the number of shares issued exceeds Nasdaq Listing Rule 5635(d).

Risks

• The market price of the common stock may fluctuate, affecting the number of shares issued upon conversion.
• The selling securityholder may sell a substantial number of shares, potentially depressing the market price.
• The company may face challenges in obtaining shareholder approval for the issuance of additional shares.
• The company's business is subject to numerous risks and uncertainties, as detailed in the Risk Factors section of the prospectus and other filings.

Future Outlook

The company intends to expand its operations into the United States, further develop and utilize its Novo Connect and Telemedicine/Telehealth Medical Technology Platform, develop and launch its Remote Patient Monitoring Medical Technology Platform, build an Intellectual Property and Patent Portfolio, expand its Posture, Stride, and Kinetic Body Movement Scanning Technologies and Protocols, and launch its Exclusive Medicinal Cannabidiol (CBD) Product Platform based in Canada.

Industry Context

The primary healthcare service sector is highly competitive in both Canada and the U.S. The company competes with other multidisciplinary primary healthcare providers, clinics, pharmacies, hospitals, and general primary care facilities. The health and wellness product industry is also highly competitive.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards.
• The document does not contain specific comparisons to comparable companies or projects.

Stakeholder Impact

• Existing shareholders may experience dilution upon conversion of the convertible note.
• The market price of the common stock could be affected by the selling securityholder's sales.
• The company's ability to raise additional capital in the future could be impacted by the convertible note and potential dilution.

Next Steps

• The selling securityholder may offer and sell the shares of common stock from time to time.
• The company may need to seek shareholder approval for the issuance of additional shares if the number of shares issued exceeds Nasdaq Listing Rule 5635(d).

Key Dates

Keywords

resale, common stock, convertible note, securities, registration statement, novo integrated sciences, streeterville capital, conversion, financing, dilution